Skip to main content

Table 4 Additional efficacy and safety data compared between the groups

From: Anti-TNF therapy for ulcerative colitis in Brazil: a comparative real-world national retrospective multicentric study from the Brazilian study group of IBD (GEDIIB)

  Adalimumab (ADA) (n=111) Infliximab (IFX) (n=282) P value
Time of treatment with anti-TNF (months) 28.93 ±23.36 41.23 ±33.14 <0.001
Secondary loss of response 44 (44.00) 96 (36.92) <0.001
Anti-TNF dose optimization 42 (40.78) 101 (38.55) <0.001
Switch of biological therapy 37 (35.58) 61 (23.28) 0.015
Colectomy 5 (4.50) 18 (6.59) 0.007
Overall adverse events 13 (11.71) 44 (16.67) 0.3902
Infectious 7 (6.93) 25 (9.51) 0.4373
Infusion or injection reactions 3 (2.97) 6 (2.42) 0.7218
Other adverse events 9 (9.0) 25 (9.54) 0.8744
Death 1 (1.02) 3 (1.17) 0.317
  1. Data presented as mean ± SD and n (%). Patients could have more than one adverse event. Calculated by Student t test or Pearson, χ2 or Fisher´s exact test